Liver cancer, which includes hepatocellular carcinoma (HCC), is the second leading cause of cancer-related death globally, responsible for more than 600,000 deaths worldwide each year.
Although this cancer type is less common in the United States, the American Cancer Society estimates that for 2018, an estimated 42,220 new cases of primary liver cancer and intrahepatic bile duct cancer will be diagnosed and about 30,200 individuals will die of these cancers nationwide.
In the U.S., rates of liver cancer in young adults have started to decline; however, the incidence of liver cancer has more than tripled over the past four decades. Nationally, death rates from liver cancer have increased by nearly three percent each year since 2000.
Effective prevention and treatment strategies for liver cancer remain an area of need. Active research in liver cancer is underway, and in recent years several new therapies, including multikinase inhibitors and checkpoint inhibitor immunotherapy, are showing promise. Historically treatment options have fallen into two broad categories, resectable (operable) and unresectable (inoperable) disease.
Source: American Cancer Society. Key Statistics About Liver Cancer.
Bucco D. Promising Liver Cancer Treatments on the Horizon. Cure Today.
In partnership with the Cancer Support Community, the American Cancer Society, and the Global Liver Institute, ACCC is conducting the Multidisciplinary Hepatocellular Carcinoma Care education program with three primary goals:
For this project, ACCC prepared an environmental scan to describe the current landscape of multidisciplinary hepatocellular carcinoma care delivery in the U.S. The scan is informed by an ACCC survey of community cancer programs, a comprehensive literature review, and insights from the project's expert Advisory Committee.